Market closed
Beam Therapeutics/$BEAM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Beam Therapeutics
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
Ticker
$BEAM
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
483
Website
BEAM Metrics
BasicAdvanced
$1.7B
-
-$4.58
1.91
-
Price and volume
Market cap
$1.7B
Beta
1.91
52-week high
$35.25
52-week low
$13.53
Average daily volume
2.9M
Financial strength
Current ratio
4.823
Quick ratio
4.673
Long term debt to equity
20.17
Total debt to equity
22.006
Management effectiveness
Return on assets (TTM)
-20.26%
Return on equity (TTM)
-43.94%
Valuation
Price to revenue (TTM)
22.03
Price to book
1.88
Price to tangible book (TTM)
1.88
Price to free cash flow (TTM)
-3.929
Growth
Revenue change (TTM)
-83.18%
Earnings per share change (TTM)
166.28%
3-year revenue growth (CAGR)
7.00%
3-year earnings per share growth (CAGR)
-7.41%
What the Analysts think about BEAM
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Beam Therapeutics stock.
BEAM Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
BEAM Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
BEAM News
AllArticlesVideos
Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress
GlobeNewsWire·2 weeks ago
Power Ranking Our Top Stock Picks of 2025
Schaeffers Research·3 weeks ago
Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Beam Therapeutics stock?
Beam Therapeutics (BEAM) has a market cap of $1.7B as of April 19, 2025.
What is the P/E ratio for Beam Therapeutics stock?
The price to earnings (P/E) ratio for Beam Therapeutics (BEAM) stock is 0 as of April 19, 2025.
Does Beam Therapeutics stock pay dividends?
No, Beam Therapeutics (BEAM) stock does not pay dividends to its shareholders as of April 19, 2025.
When is the next Beam Therapeutics dividend payment date?
Beam Therapeutics (BEAM) stock does not pay dividends to its shareholders.
What is the beta indicator for Beam Therapeutics?
Beam Therapeutics (BEAM) has a beta rating of 1.91. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.